BTIS
PCRX icon

BB&T Investment Services’s Pacira BioSciences PCRX Stock Holding History

BB&T Investment Services’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-60
Closed -$3K – 1195
2017
Q1 		$3K Buy
+60
New +$2.59K ﹤0.01% 891

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

BB&T Investment Services's PCRX Position: Q2 2017 in Review

BB&T Investment Services sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 60 shares — an estimated $3K sold.

BB&T Investment Services first reported a position in PCRX in Q1 2017 and held it in 1 quarter. The position peaked at $3K in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • BB&T Investment Services reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • BB&T Investment Services sold 60 Pacira BioSciences shares in Q2 2017, an estimated $3K.
  • BB&T Investment Services first reported a position in Pacira BioSciences in Q1 2017 and held it in 1 quarter.
  • BB&T Investment Services's Pacira BioSciences position peaked at $3K in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on BB&T Investment Services's 13F filing for Q2 2017, filed 15 Aug 2017.